Accumulus Synergy Announces Appointment of its New CEO

Accumulus Synergy Announces Appointment of its New CEO

Healthcare Tech Outlook | Wednesday, June 16, 2021

Accumulus Synergy was founded on July 13, 2020, to create a cloud-based platform for data and information sharing that can change how the biopharmaceutical industry interacts with health authorities.

FREMONT, CA: Accumulus Synergy, a non-profit organization dedicated to facilitating real-time collaboration and data exchange between industry and health authorities worldwide, has named Francisco (Frank) Nogueira as its new CEO. Nogueira previously worked at Roche as a vice president of regulatory affairs and has been the interim CEO of Accumulus since the fall of 2020.

“One of the learnings from the Covid-19 pandemic is that the biopharma world, including industry, academia and government, can move extremely rapidly in the face of an unprecedented crisis. To go from first sequencing of a new virus to multiple neutralizing antibodies and vaccines in under a year is truly remarkable. At Accumulus Synergy, the vision is to dramatically accelerate the delivery of critical therapies to the citizens of the world by reimagining the interaction and information exchange between stakeholders in the healthcare ecosystem to streamline the regulatory lifecycle. These changes will not happen overnight, but I am confident that Accumulus Synergy will be have culture that is entrepreneurial, agile and fosters innovation. We will strive to be a magnet for top talent and diverse thinkers based on our social remit, ground-breaking technology and opportunity to make an impact for patients,” said Nogueira.

Accumulus Synergy was founded on July 13, 2020, to create a cloud-based platform for data and information sharing that can change how the biopharmaceutical industry interacts with health authorities. The goal of the common-platform approach to data sharing is to speed up the regulatory process by leveraging modern technology and platforms for data interchange to benefit patients, lower the cost of innovation, and ultimately bring new safe, and effective medicines to patients faster.

“After an extensive search, the Board of Directors has concluded that Nogueira is the ideal candidate to lead the exciting vision of Accumulus Synergy. In his role as Interim CEO, Nogueira has demonstrated outstanding leadership and made excellent progress on key company goals. The Board will provide Mr. Nogueira with their full support in building a powerful organization that meets both the short-term goals and long-term aspirations,” said Jeremy Chadwick, Ph.D., chairman of the Board of Directors at Accumulus Synergy and a senior vice president and head of Global Development Office at Takeda Pharmaceuticals.

Amgen, Astellas, Bristol-Myers Squibb, GSK, Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), Lilly, Pfizer, Sanofi, Roche, and Takeda are among the initial members of Accumulus Synergy, which have provided funding to support the platform and initial applications.

Weekly Brief